 This study conducted a network meta-analysis to compare the efficacy of six biologics in achieving complete resolution of nail psoriasis, NP, at week 24 to 26 in patients with moderate to severe psoriasis and concomitant NP. The results showed that Ixacizumab had the highest probability of achieving complete resolution of NP, followed by Brodalumab, Adalamumab, Goosalcumab, Ustakinumab, and Infliximab. Therefore, Ixacizumab is the most effective biologic in achieving complete resolution of NP at week 24 to 26 among approved biologics. This article was authored by Christian Reich, Kerdin Konrad, Lars Eric Christensen, and others.